tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

DiaMedica Therapeutics upgraded to Outperform from Perform at Oppenheimer

Oppenheimer analyst Francois Brisebois upgraded DiaMedica Therapeutics to Outperform from Perform with a $7 price target.

Meet Your ETF AI Analyst

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on DMAC:

Disclaimer & DisclosureReport an Issue

1